Organization | Actuate Therapeutics Inc.

Actuate Therapeutics Inc. Report issue

For profit Phase 2

Founded: Fort Worth TX United States (2015)

Organization Overview

First Clinical Trial

2018

NCT03678883

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Actuate Therapeutics | Actuate Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (14)

9-ing-41 (9 trials)

carboplatin (paraplatin) (3 trials)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (4 trials)

irinotecan (Camptosar) (3 trials)

leucovorin (1 trial)

lomustine (1 trial)

losartan (cozaar) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (2 trials)

retifanlimab (Zynyz) (1 trial)

ruxolitinib (jakafi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bone Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Meningioma (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neuroblastoma (Phase 1)

Pancreatic Neoplasms (Phase 2)

Primary Myelofibrosis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 14